(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application - 2the 6 Shrewd Beds for seniors: A Complete Survey
- 3Anti-war protests held across Israel under wartime gathering limits
- 4Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- 5Jasmine Crockett in, Colin Allred out: A major shakeup for Democrats in their quest to finally win a Senate seat in Texas
- How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- Manual for Financial plan Agreeable PC
- Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- Vote In favor of Your Favored Distributed computing Administration
- Must-Have Cooking Machine in Your Kitchen
- Police break up illegal chicken slaughter in Germany
- Pick the Ideal Family Feline Variety for Your Home
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- Artemis II crew take new photo of far side of the moon
